Literature DB >> 25126165

Celastrol may have an anti-atherosclerosis effect in a rabbit experimental carotid atherosclerosis model.

Feng Zhu1, Cai Li1, Xiao-Ping Jin1, Shou-Xiang Weng2, Li-Long Fan3, Zhou Zheng1, Wei-Ling Li1, Feng Wang1, Wan-Fen Wang1, Xiao-Fei Hu1, Chen-Ling Lv1, Peng Liu1.   

Abstract

BACKGROUND: Celastrol may have an anti-atherosclerosis effect. This study aimed to investigate if celastrol had an anti-AS effect using a rabbit experimental carotid atherosclerosis model.
METHODS: Forty male Japanese white rabbits were divided into the sham group (normal diet), the model group (high fat diet), the group treated with celastrol (high fat diet) and the group treated with atorvastatin (high fat diet) randomly. The rabbits fed a high fat diet underwent balloon injury of the right common carotid artery and were treated with dimethyl sulfoxide (DMSO) (the model group, 3.5 ml/kg/d), celastrol and its dissolvent DMSO (the celastrol group, 1 mg/kg/d and 3.5 ml/kg/d) and atorvastatin and its dissolvent DMSO (the atorvastatin group, 2.5 mg/kg/d and 3.5 ml/kg/d) for 12 weeks by gavage.
RESULTS: The ratio of the plaque area and the arterial wall cross-section area in the celastrol group was significantly less than the model group (P < 0.001), and there was no significant difference compared with the atorvastatin group. The serum level of LDL-C of the celastrol group was significantly lower than the model group (P = 0.014), and there was no significant difference compared with the atorvastatin group. The expression of VEGF in the celastrol group was significantly less compared with the model group (P = 0.014), whereas the expression of VEGF in the atorvastatin group and the model group showed no significant differences.
CONCLUSION: Our findings suggest that celastrol effectively reduced the plaque ratio, decreased the serum levels of LDL and downregulated the expression of VEGF, suggesting an anti-AS effect of celastrol.

Entities:  

Keywords:  Celastrol; balloon injury; carotid artery disease; low-density lipoprotein cholesterol; vascular endothelial growth factor

Year:  2014        PMID: 25126165      PMCID: PMC4132129     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

Review 1.  Identifying the carotid 'high risk' plaque: is it still a riddle wrapped up in an enigma?

Authors:  J Golledge; D-A Siew
Journal:  Eur J Vasc Endovasc Surg       Date:  2007-11-05       Impact factor: 7.069

2.  Inhibitory action of Celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway.

Authors:  Lili Huang; Zefu Zhang; Sheng Zhang; Jinghua Ren; Ruiguang Zhang; Hui Zeng; Qingfeng Li; Gang Wu
Journal:  Int J Mol Med       Date:  2011-01-18       Impact factor: 4.101

3.  Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis.

Authors:  Mark Fisher; Annlia Paganini-Hill; Aldana Martin; Michele Cosgrove; James F Toole; Henry J M Barnett; John Norris
Journal:  Stroke       Date:  2005-01-13       Impact factor: 7.914

4.  Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Larry B Goldstein; Cheryl D Bushnell; Robert J Adams; Lawrence J Appel; Lynne T Braun; Seemant Chaturvedi; Mark A Creager; Antonio Culebras; Robert H Eckel; Robert G Hart; Judith A Hinchey; Virginia J Howard; Edward C Jauch; Steven R Levine; James F Meschia; Wesley S Moore; J V Ian Nixon; Thomas A Pearson
Journal:  Stroke       Date:  2010-12-02       Impact factor: 7.914

Review 5.  Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.

Authors:  Kevin A Bybee; John H Lee; James H O'Keefe
Journal:  Curr Med Res Opin       Date:  2008-03-20       Impact factor: 2.580

6.  Celastrol inhibits interleukin-17A-stimulated rheumatoid fibroblast-like synoviocyte migration and invasion through suppression of NF-κB-mediated matrix metalloproteinase-9 expression.

Authors:  Guo-qing Li; Yu Zhang; Dan Liu; Ya-yun Qian; Hua Zhang; Shi-yu Guo; Masataka Sunagawa; Tadashi Hisamitsu; Yan-qing Liu
Journal:  Int Immunopharmacol       Date:  2012-09-03       Impact factor: 4.932

Review 7.  Immune and inflammatory mechanisms of atherosclerosis (*).

Authors:  Elena Galkina; Klaus Ley
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 8.  The main anticancer bullets of the Chinese medicinal herb, thunder god vine.

Authors:  Zi Liu; Liang Ma; Guang-Biao Zhou
Journal:  Molecules       Date:  2011-06-23       Impact factor: 4.411

9.  A study to correlate carotid intima thickness by B-mode ultrasonography in patients documented with coronary artery disease.

Authors:  Shiran Shetty; Peter George; B M Venkatesha; Jayaprakash Alva
Journal:  Heart Views       Date:  2011-10

10.  In vivo optical coherence tomography of experimental thrombosis in a rabbit carotid model.

Authors:  L Meng; B Lv; S Zhang; B Yv
Journal:  Heart       Date:  2007-10-18       Impact factor: 5.994

View more
  10 in total

1.  Effects and mechanisms of icariin on atherosclerosis.

Authors:  Yanwu Hu; Kai Liu; Mengtong Yan; Yang Zhang; Yadi Wang; Liqun Ren
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Celastrol and Its Role in Controlling Chronic Diseases.

Authors:  Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

3.  Autologous Bone Marrow Mononuclear Cell Transplantation Delays Progression of Carotid Atherosclerosis in Rabbits.

Authors:  Kefei Cui; Xiao Ma; Lie Yu; Chao Jiang; Chao Fu; Xiaojie Fu; Xiaofang Yu; Yuanjing Huang; Suyun Hou; Caifeng Si; Zhengguang Chen; Jing Yu; Jieru Wan; Jian Wang
Journal:  Mol Neurobiol       Date:  2015-08-02       Impact factor: 5.590

Review 4.  Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.

Authors:  Vítor Teixeira; Lai-Shan Tam
Journal:  Front Med (Lausanne)       Date:  2018-01-29

Review 5.  Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases.

Authors:  Rita Cascão; João E Fonseca; Luis F Moita
Journal:  Front Med (Lausanne)       Date:  2017-06-15

6.  Early Celastrol Administration Prevents Ketamine-Induced Psychotic-Like Behavioral Dysfunctions, Oxidative Stress and IL-10 Reduction in The Cerebellum of Adult Mice.

Authors:  Stefania Schiavone; Paolo Tucci; Luigia Trabace; Maria Grazia Morgese
Journal:  Molecules       Date:  2019-11-05       Impact factor: 4.411

Review 7.  Celastrol: A Promising Agent Fighting against Cardiovascular Diseases.

Authors:  Zhexi Li; Jingyi Zhang; Xulei Duan; Guoan Zhao; Min Zhang
Journal:  Antioxidants (Basel)       Date:  2022-08-18

8.  Effect of celastrol on toll‑like receptor 4‑mediated inflammatory response in free fatty acid‑induced HepG2 cells.

Authors:  Li-Ping Han; Bei Sun; Chun-Jun Li; Yun Xie; Li-Ming Chen
Journal:  Int J Mol Med       Date:  2018-07-12       Impact factor: 4.101

9.  Celastrol Alleviates Aortic Valve Calcification Via Inhibition of NADPH Oxidase 2 in Valvular Interstitial Cells.

Authors:  Huibing Liu; Libo Wang; Yating Pan; Xuehui Wang; Yuan Ding; Chaoyuan Zhou; Ajay M Shah; Guoan Zhao; Min Zhang
Journal:  JACC Basic Transl Sci       Date:  2019-12-18

10.  Celastrol ameliorates vascular neointimal hyperplasia through Wnt5a-involved autophagy.

Authors:  Ya-Ning Shi; Le-Ping Liu; Chang-Feng Deng; Tan-Jun Zhao; Zhe Shi; Jian-Ye Yan; Yong-Zhen Gong; Duan-Fang Liao; Li Qin
Journal:  Int J Biol Sci       Date:  2021-06-22       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.